Charmacy Pharmaceutical Co., Ltd. provided financial guidance for the 11 months ended 30 November 2022. For the period, the Group expected to record an unaudited net profit attributable to shareholders of the parent company for the 11 months ended 30 November 2022 of approximately RMB 32 million (the Profit Alert), which represents a significant increase as compared with: the audited net profit attributable to shareholders of the parent company for the year ended 31 December 2021 of approximately RMB 23 million; and the unaudited net profit attributable to shareholders of the parent company for the six months ended 30 June 2022 of approximately RMB 21 million.